Evidence map›Paper›PMID 33963482›Full record

ReviewCancer metastasis reviews2021

Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.

Molly A Nelson, Worapol Ngamcherdtrakul, Shiuh-Wen Luoh, Wassana Yantasee

Open access · greenAbstract readReview
In one paragraph

Review in Cancer metastasis reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 2 pooled it
8.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. The prognostic values of FOXP3Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Pooled it
  3. The density of tumour infiltrating lymphocytes in oesophago-gastric cancer varies with disease stage, geographical region and treatment: a post hoc analysis of nine phase III clinical trials.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  4. Article
  5. Review
  6. Regulatory B cells andBiomolecules & biomedicine · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Advances in tumor-infiltrating B lymphocytes.Central-European journal of immunology · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Molly A NelsonPDX Pharmaceuticals, Inc., Portland, OR, USA.
Worapol NgamcherdtrakulPDX Pharmaceuticals, Inc., Portland, OR, USA.
Shiuh-Wen LuohVA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Wassana YantaseePDX Pharmaceuticals, Inc., Portland, OR, USA. yantasee@ohsu.edu.ORCID 0000-0002-0989-363X
Oregon Health & Science University · USPDX Pharmaceuticals (United States) · US

Funding

Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancerR44CA217534 · NCI · PDX PHARMACEUTICALS, INC. · PI GRAY, JOE W., NGAMCHERDTRAKUL, WORAPOL · 2017 to 2019
$1.7M
NCI NIH HHS R44 CA217534
6 · The paper itself

Abstract

Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells and immune cells in a variety of different ways, leading to either a pro-tumor or antitumor effect. Tumor-infiltrating CD8

Indexed as

AnimalsB-LymphocytesBreast NeoplasmsCD8-Positive T-LymphocytesFemaleHumansImmune Checkpoint InhibitorsImmunotherapyImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingNatural Killer T-CellsT-Lymphocytes, RegulatoryImmune Checkpoint InhibitorsBreast cancerImmunotherapyT cellsTILsTumor microenvironment

Identifiers

PMID33963482
PMCPMC8424653
OpenAlexW3159523017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.